Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk
- PMID: 22982463
- PMCID: PMC3499946
- DOI: 10.1161/ATVBAHA.112.253930
Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk
Abstract
Objective: Diminished serum paraoxonase and arylesterase activities (measures of paraoxonase-1 [PON-1] function) in humans have been linked to heightened systemic oxidative stress and atherosclerosis risk. The clinical prognostic use of measuring distinct PON-1 activities has not been established, and the genetic determinants of PON-1 activities are not known.
Methods and results: We established analytically robust high-throughput assays for serum paraoxonase and arylesterase activities and measured these in 3668 stable subjects undergoing elective coronary angiography without acute coronary syndrome and were prospectively followed for major adverse cardiovascular events (MACE= death, myocardial infarction, stroke) over 3 years. Low serum arylesterase and paraoxonase activities were both associated with increased risk for MACE, with arylesterase activity showing greatest prognostic value (quartile 4 versus quartile 1; hazard ratio 2.63; 95% CI, 1.97-3.50; P<0.01). Arylesterase remained significant after adjusting for traditional risk factors, C-reactive protein, and creatinine clearance (hazard ratio, 2.20; 95% CI, 1.60-3.02; P<0.01), predicted future development of MACE in both primary and secondary prevention populations, and reclassified risk categories incrementally to traditional clinical variables. A genome-wide association study identified distinct single nucleotide polymorphisms within the PON-1 gene that were highly significantly associated with serum paraoxonase (1.18×10(-303)) or arylesterase (4.99×10(-116)) activity but these variants were not associated with either 3-year MACE risk in an angiographic cohort (n=2136) or history of either coronary artery disease or myocardial infarction in the Coronary Artery Disease Genome-Wide Replication and Meta-Analysis consortium (n≈80 000 subjects).
Conclusions: Diminished serum arylesterase activity, but not the genetic determinants of PON-1 functional measures, provides incremental prognostic value and clinical reclassification of stable subjects at risk of developing MACE.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3499946/bin/nihms413066f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3499946/bin/nihms413066f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3499946/bin/nihms413066f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3499946/bin/nihms413066f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3499946/bin/nihms413066f5.gif)
Similar articles
-
Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis.Dis Markers. 2022 Mar 10;2022:4264314. doi: 10.1155/2022/4264314. eCollection 2022. Dis Markers. 2022. PMID: 35308142 Free PMC article. Review.
-
Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies.Atherosclerosis. 2016 Feb;245:143-54. doi: 10.1016/j.atherosclerosis.2015.12.021. Epub 2015 Dec 19. Atherosclerosis. 2016. PMID: 26724525 Review.
-
Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease.J Am Heart Assoc. 2013 Apr 4;2(2):e000104. doi: 10.1161/JAHA.112.000104. J Am Heart Assoc. 2013. PMID: 23557751 Free PMC article.
-
Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure.Circ Heart Fail. 2011 Jan;4(1):59-64. doi: 10.1161/CIRCHEARTFAILURE.110.958348. Epub 2010 Nov 9. Circ Heart Fail. 2011. PMID: 21062973 Free PMC article.
-
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.JAMA. 2008 Mar 19;299(11):1265-76. doi: 10.1001/jama.299.11.1265. JAMA. 2008. PMID: 18349088 Free PMC article.
Cited by
-
Effect of Exercise Repetitions on Arylesterase Activity of PON1 in Plasma of Average-Trained Men-The Dissociation between Activity and Concentration.Antioxidants (Basel). 2023 Jun 17;12(6):1296. doi: 10.3390/antiox12061296. Antioxidants (Basel). 2023. PMID: 37372026 Free PMC article.
-
Proteomic Exploration of Paraoxonase 1 Function in Health and Disease.Int J Mol Sci. 2023 Apr 24;24(9):7764. doi: 10.3390/ijms24097764. Int J Mol Sci. 2023. PMID: 37175471 Free PMC article. Review.
-
Paraoxonases at the Heart of Neurological Disorders.Int J Mol Sci. 2023 Apr 7;24(8):6881. doi: 10.3390/ijms24086881. Int J Mol Sci. 2023. PMID: 37108044 Free PMC article. Review.
-
Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure.Biomedicines. 2023 Mar 15;11(3):917. doi: 10.3390/biomedicines11030917. Biomedicines. 2023. PMID: 36979896 Free PMC article. Review.
-
Depletion of Paraoxonase 1 (Pon1) Dysregulates mTOR, Autophagy, and Accelerates Amyloid Beta Accumulation in Mice.Cells. 2023 Feb 26;12(5):746. doi: 10.3390/cells12050746. Cells. 2023. PMID: 36899882 Free PMC article.
References
-
- Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–325. - PubMed
-
- Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (pon1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact. 1999;119–120:429–438. - PubMed
-
- Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–287. - PubMed
-
- Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473–480. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 ES021801/ES/NIEHS NIH HHS/United States
- 1P20HL113452/HL/NHLBI NIH HHS/United States
- R01HL103866/HL/NHLBI NIH HHS/United States
- R01 HL103931/HL/NHLBI NIH HHS/United States
- R01ES021801/ES/NIEHS NIH HHS/United States
- P01 HL076491/HL/NHLBI NIH HHS/United States
- P20 HL113452/HL/NHLBI NIH HHS/United States
- P01HL098055/HL/NHLBI NIH HHS/United States
- MOP77682/CAPMC/ CIHR/Canada
- MOP-82810/CAPMC/ CIHR/Canada
- UL1 TR000439/TR/NCATS NIH HHS/United States
- 1R01HL103931/HL/NHLBI NIH HHS/United States
- MOP172605/CAPMC/ CIHR/Canada
- R01 HL103866/HL/NHLBI NIH HHS/United States
- P01HL076491-055328/HL/NHLBI NIH HHS/United States
- P01 HL098055/HL/NHLBI NIH HHS/United States
- MRC_/Medical Research Council/United Kingdom
- 5P01HL103453/HL/NHLBI NIH HHS/United States
- P01 HL103453/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous